Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
14 hedge funds and large institutions have $1.65M invested in Rosetta Genomics Ltd. in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 4 closing their positions.
13% less funds holding
Funds holding: 16 → 14 (-2)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
47% less capital invested
Capital invested by funds: $3.12M → $1.65M (-$1.48M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
97% less call options, than puts
Call options by funds: $6K | Put options by funds: $223K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$79K |
| 2 |
Renaissance Technologies
New York
|
+$69.7K |
| 3 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
+$37.9K |
| 4 |
Morgan Stanley
New York
|
+$9.86K |
| 5 |
AIG
American International Group
New York
|
+$1.77K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$1.11M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$62.2K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
-$46K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$44K |
| 5 |
Citigroup
New York
|
-$26.7K |
ROSG Hedge Fund Activity: Q3 2014 in Review
14 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q3 2014, worth a combined $1.65M — down 47% from $3.12M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ROSG and 2 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $79K. The largest seller was B. Riley Wealth Advisors, exiting entirely with an estimated $1.11M sold.
- 14 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q3 2014, down from 16 in Q2 2014.
- Funds reported $1.65M of Rosetta Genomics Ltd. stock for Q3 2014, down 47% quarter-over-quarter.
- 2 funds opened new Rosetta Genomics Ltd. positions in Q3 2014 and 4 closed out, a net change of -2 holders.
- The largest Rosetta Genomics Ltd. buyer in Q3 2014 was Goldman Sachs, an estimated $79K added.
- The largest Rosetta Genomics Ltd. seller in Q3 2014 was B. Riley Wealth Advisors, an estimated $1.11M sold.
Based on aggregated 13F filings for Q3 2014.